Galapagos NV (NASDAQ:GLPG) was the target of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 403,300 shares, a drop of 27.4% from the August 31st total of 555,345 shares. Based on an average trading volume of 105,234 shares, the days-to-cover ratio is presently 3.8 days.

Shares of Galapagos NV (NASDAQ:GLPG) opened at 102.75 on Tuesday. The firm has a 50-day moving average price of $100.87 and a 200 day moving average price of $100.87. The stock’s market cap is $5.23 billion. Galapagos NV has a 12-month low of $57.16 and a 12-month high of $103.54.

A number of large investors have recently made changes to their positions in the stock. Cookson Peirce & Co. Inc. grew its stake in Galapagos NV by 0.7% in the second quarter. Cookson Peirce & Co. Inc. now owns 3,045 shares of the biotechnology company’s stock worth $233,000 after purchasing an additional 20 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in Galapagos NV during the 2nd quarter worth $214,000. Cubist Systematic Strategies LLC purchased a new position in Galapagos NV during the 2nd quarter worth $704,000. EcoR1 Capital LLC increased its holdings in Galapagos NV by 5.0% during the 2nd quarter. EcoR1 Capital LLC now owns 578,505 shares of the biotechnology company’s stock worth $44,267,000 after purchasing an additional 27,464 shares during the period. Finally, DAFNA Capital Management LLC raised its position in Galapagos NV by 9.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 38,609 shares of the biotechnology company’s stock valued at $2,954,000 after purchasing an additional 3,250 shares in the last quarter. 23.62% of the stock is currently owned by institutional investors.

GLPG has been the subject of several recent research reports. Zacks Investment Research downgraded Galapagos NV from a “hold” rating to a “sell” rating in a research report on Monday. Stifel Nicolaus upgraded shares of Galapagos NV from a “hold” rating to a “buy” rating and raised their target price for the stock from $83.00 to $101.00 in a report on Friday, August 11th. Cowen and Company restated a “buy” rating on shares of Galapagos NV in a report on Thursday, August 10th. Morgan Stanley reaffirmed an “overweight” rating and issued a $92.00 target price on shares of Galapagos NV in a research note on Thursday, August 10th. Finally, BidaskClub downgraded shares of Galapagos NV from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the stock. Galapagos NV has a consensus rating of “Buy” and a consensus price target of $103.71.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.watchlistnews.com/short-interest-in-galapagos-nv-glpg-declines-by-27-4/1604164.html.

About Galapagos NV

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with Analyst Ratings Network's FREE daily email newsletter.